35 results about "Endometrium thickness" patented technology

The invention provides application of decidua NK cells and decidua NK cell exosomes from cell subsets in preparing drugs and auxiliary therapeutic agents for treating diseases related to infertility.Experiments prove that the exosomes treat endometrium growth disorders by promoting endometrial thickness increasing, improving endometrial cell activity, reducing endometrial cell damage, promoting VEGF expression, maintaining stem features of endometrium matrix cells and stimulating proliferation, so that the pregnancy success rate of endometrium damage model mice is increased to 50-70% from 20%; and the exosomes treat diseases related to maternal-fetal immunologic tolerance disorders by playing a role of immunologic tolerance, reducing a spontaneous abortion rate and improving a help T lymphocyte level. Besides, the exosomes can effectively increase the developmental rate of zygotes fertilized no matter in vitro or in vivo in a multiple mode, meanwhile, an in-vitro fertilization rate, an implantation rate of implantation and a birth rate are also increased, and positive assisting effects on infertility treatment are achieved.

The invention discloses traditional Chinese medicine for treating thin endometrium. The traditional Chinese medicine is mainly prepared from radix codonopsis, semen euryales, cornu cervi degelatinatum, fructus psoraleae, herba cistanches, rhizoma dioscoreae, pulp of cornus, radix salviae miltiorrhizae, caulis spatholobi, common ginger, trogopterus dung processed with wine and radix glycyrrhizae preparata. The formula composed of raw material medicine tonifies the kidney, activates blood, replenishes essence and cultivates cells, therefore, thickness of endometrium of females is enhanced, the menstrual blood volume is increased, capability of gestating babies of females is improved, and clinical treatment efficiency of the traditional Chinese medicine is 97.78%.

The invention belongs to the technical field of obstetrical and gynecology, and more specifically relates to a guided tissue regeneration membrane for compositing BMSCs, a patch and a preparation method thereof. The method prepares a single cell suspension by trypsinizing the BMSCs in a growth phase, and uniformly drops the single cell suspension into the guided tissue regeneration membrane, and then cultures the material in an incubator to obtain the guided tissue regeneration membrane for compositing the mesenchymal stem cells. The BMSCs of the invention are used as an active component for treating endometrial damage, the obtaining is convenient, local microenvironment and immune regulation can be improved by secretion of growth factors, the guided tissue regeneration membrane has good biocompatibility, promotes damage to endometrial repair, and increases endometrium thickness and vascular density.

The invention relates to the technical field of medicines, and provides applications of uterine cavity fluid-derived exosome in preparation of drugs and adjuvant therapeutic agents for treating infertility related diseases. Through the verification of experiments, exosome realizes the treatment or relieving of endometrial growth disorders by promoting the increasing of the thickness of endometrium, enhancing the activity of endometrial cells, reducing the damages to intimal cells, promoting VEGF expression, maintaining the dryness of endometrial stromal cells and stimulating proliferation; andthrough the realizing of the treating or relieving of maternal-fetal immune tolerance disorder-related diseases by achieving immune tolerance effects, treating spontaneous abortion and enhancing T helper lymphocyte levels, a novel theoretical basis can be provided for infertility treatment. In addition, for both fertilized eggs being fertilized in vivo or fertilized in vitro, the exosome can effectively enhance developmental rates in multiples; and implantation rates and farrowing rates of in vitro fertilization transplantation can be increased as well, so that positive auxiliary effects on infertility treatment can be achieved.

The invention discloses a preparation method and application of a composite decellularized amniotic membrane of endometrial stem cells in the technical field related to physiological health care, including preparation of complete amniotic membrane tissue, preparation of a translucent amniotic membrane, immersion disinfection, decellularization treatment, preparation of a stem cell amniotic membrane culture system, preparation and cultivation of endometrial stem cell composite decellularized amniotic membrane and other processes as well as cryopreservation, thawing and application. The endometrial stem cell composite decellularized amniotic membrane prepared by the method is applied to the preparation of endometrial repair materials, is transplanted into the endometrial injury site for repair of endometrial damage and increase the thickness of the endometrium; the decellularized amniotic membrane completely removes cells and nucleic acids, and does not produce rejection reactions in thebody; through combination of menstrual blood stem cells or endometrium stem cells with the decellularized amniotic membrane, the cells are homologous to endometrial cells, and the repair effect is good; the use of hormones in repair is completely excluded to avoid interference with the internal secretion of a human body.

The invention provides an application of decidua NK cells and cell subsets thereof in preparation of medicines for treating infertility related diseases. Through experimental verification, according to the decidua NK cell and the cell subset thereof, endometrial growth disorder diseases are treated by promoting endometrial thickness increase, enhancing endometrial cell viability, reducing endometrial cell damage, promoting VEGF expression, maintaining endometrial stromal cell dryness and stimulating proliferation; the pregnancy success rate of endometrial injury model mice is increased from 30% to 60-70%; by exerting the immune tolerance effect, reducing the spontaneous abortion rate and improving the T helper lymphocyte level to treat maternal fetal immune tolerance disorder related diseases, a new way is provided for treatment of infertility.

The invention relates to a traditional Chinese medicine for treating functional uterine bleeding. If traditional Chinese medicines, which are commonly used in the field of functional uterine bleeding and comprise saururus chinensis, red cockscomb and caulis spatholobi, are singly used, only a slight hematostatic function is achieved and obvious curative effect in treating metrorrhagia is not achieved. If two medicines are used together, only a certain curative effect on postpartum flooding is achieved, but is not obvious. The traditional Chinese medicine for treating functional uterine bleeding is prepared from the following components in parts by weight: 14 to 30 parts of saururus chinensis, 10 to 20 parts of red cockscomb and 9 to 20 parts of caulis spatholobi. The saururus chinensis, the red cockscomb and the caulis spatholobi are used together, so the traditional Chinese medicine for treating functional uterine bleeding has anti-inflammatory and hemostatic effects, can reduce the thickness of endometrium and reduce bleeding amount, can also promote follicle proliferation and maturity, and has a good curative effect on anovulatory metrorrhagia. The secrete prescription has good curative effects on postpartum flooding and anovulatory metrorrhagia, and can cure the metrorrhagia temporarily and permanently by finally adjusting and improving the endocrine function of an organism.

The invention discloses an endometrium thickness automatic measurement method and system based on wavelet transform, and relates to an endometrium thickness automatic measurement method based on wavelet transform, which comprises the following steps: S1, receiving an acquired standard longitudinal cutting image corresponding to an endometrium; S2, preprocessing the received endometrium image to obtain a preprocessed endometrium image; S3, performing endometrial image segmentation on the preprocessed endometrial image based on multi-resolution fast wavelet transform to obtain a segmented endometrial image; and S4, according to the obtained segmented endometrium image, automatically measuring the maximum distance between the endometrium basal layers, namely the thickness of the endometrium.According to the image segmentation method based on wavelet transform, the endometrium image is accurately segmented, and the endometrium thickness is automatically measured to serve as a clinical diagnosis basis. The process does not need human intervention, and an automatic measurement result can be quickly and effectively output.

The invention discloses application of FoxM1 in preparation of a reagent for diagnosing and treating intrauterine adhesion diseases. The invention relates to application of FoxM1 as a detection target in preparation of an intrauterine adhesion diagnostic reagent. The invention relates to application of FoxM1 in preparation of a medicine for treating diseases caused by uterine fibrosis. Experiments find that expression of FoxM1 in endometrial tissues of an intrauterine adhesion patient is remarkably reduced, particularly, reduction of epithelial cells is most remarkable, and the expression level of the FoxM1 has certain positive correlation with the endometrial thickness of the intrauterine adhesion patient. The ROC diagram shows that the FoxM1 has a good diagnostic value for intrauterine adhesion. An in-vitro result shows that the expression level of the FoxM1 is also obviously reduced in the TGF beta1-induced epithelial cell fibrosis. Therefore, FoxM1 can play an important role in detection and treatment of intrauterine adhesion, and can be used for clinical diagnosis and treatment of intrauterine adhesion.

The invention discloses novel application of a medicinal composition adopting epimedium, glossy privet fruit, radix polygonati officinalis, black soybean, sophora flower, mulberry, raspberry, American ginseng, donkey-hide gelatin, paecilomyces hepialid filament powder as main raw materials in preparing medicaments for treating diminished ovarian reserve and/or promoting endometrial development. The medicinal composition can be used for improving the ovarian reserve function, and promoting endometrial development by improving gynecologic endocrine function and increasing endometrium thickness, and has a wide application prospect.

The invention belongs to the technical field of traditional Chinese medicine, and particularly discloses a medicine for treating infertility and a preparation method thereof. The medicine is prepared from fried semen cuscutae, cornu cervi degelatinatum, roasted morinda officinalis, fried eucommia ulmoides, fried teasel roots, fried Chinese yam, fried gorgon fruits, fructus lycii, amomum villosum lour, fried rhizoma atractylodis macrocephalae, codonopsis pilosula, prepared rehmannia roots, angelica sinensis, roasted astragalus membranaceus and roasted liquorice. The medicine for treating infertility is beneficial for increasing the thickness of the endometrium, enhancing the follicle tension, recovering normal development of follicles and enhancing pregnancy assistance.

The invention discloses a pharmaceutical composition for warming kidney and tonifying yang. The pharmaceutical composition is prepared from the following raw material medicines in parts by mass of 7-13 parts of herba epimedii, 7-13 parts of rhizoma drynariae and 7-13 parts of herba cistanche. The kidney warming and yang tonifying compound can improve the uterus microenvironment from the aspects of serum sex hormone, endometrial thickness and gland function, female progestational hormone receptor expression, uterus microvessel density, uterus local area factors and the like, can also improve the ovum function, enhance ovarian reserve, promote oocyte maturation and inhibit cell excessive apoptosis, the occurrence of abnormal ova and atresia follicles is reduced, the positive improvement effect on Chong and Ren deficiency reproductive disorder is achieved, and the pregnancy outcome is changed.

The invention provides application of a pharmaceutical composition in preparation of a medicine for preventing and/or treating thin endometrium or infertility. The pharmaceutical composition is a preparation prepared from the following raw material medicines in parts by weight of 7-13 parts of herba epimedii, 7-13 parts of rhizoma drynariae and 7-13 parts of herba cistanche. Experiments prove that after the pharmaceutical composition provided by the invention is taken, the endometrial receptivity of a thin endometrial (kidney-yang deficiency syndrome) patient is remarkably improved, the endometrial thickness, the female progestational hormone level in the middle stage of corpus luteum and the endometrial blood supply of the patient are remarkably improved, and the total effective rate of treatment is up to 87.88%. The pharmaceutical composition provided by the invention is precise and appropriate in compatibility, and has a wide prospect in preparation of medicines for preventing and/or treating kidney-yang deficiency type thin endometrium and thin endometrial infertility.

The invention discloses a traditional Chinese medicine composition for treating hypomenorrhea and infertility caused by thin endometrium and a preparation method thereof. The traditional Chinese medicine composition is prepared from 1-6 parts of roasted tortoise plastron, 1-6 parts of roasted turtle shell, 16 parts of prepared rehmannia root, 1-9 parts of pulp of dogwood fruit, 1-6 parts of parched white peony root, 0.5-3 part of fried angelica sinensis, 1-9 parts of ligusticum wallichii, 1.5-9 parts of spina date seed, 1-9 parts of roasted rhizoma anemarrhenae, 1-6 parts of poria cocos in Yunnan, 1-6 parts of fried codonopsis pilosula and 1-12 parts of roasted rhizoma atractylodis macrocephalae. A formula is screened through a large number of clinical researches, and a research result shows that the traditional Chinese medicine composition can effectively improve the syndromes of kidney yin deficiency type hypomenorrhea and infertility, increase the menorrhea, promote endometrial hyperplasia and follicle development in the later menstruation period, improve the levels of serum E2 and LH in the ovulation period, improve the levels of E2 and P in the middle luteal stage, increase the thickness of the endometrium in the middle-stage luteum, increase the volume of the endometrium and enrich blood perfusion under the endometrium in the middle-stage luteum, so that the endometrium receptivity is improved, embryo implantation is promoted to help pregnancy, and the traditional Chinese medicine composition is free of toxic and side effects and safe and reliable in medication.

The invention belongs to the field of medicine, and in particular relates to a new application of isosorbide mononitrate and a new dosage form corresponding to the new application; specifically, it is the preparation of isosorbide mononitrate in the preparation of drugs for promoting endometrium development use. The promotion of endometrial development is specifically achieved by repairing and improving the endometrium to increase the thickness of the endometrium, or by promoting the development of uterine glands, or by promoting the development of uterine stroma. The drug prepared to adapt to the above four new uses is a topical vaginal administration preparation, that is, a preparation prepared by adding an effective amount of isosorbide mononitrate as an active ingredient and adding pharmaceutically acceptable auxiliary materials. After vaginal administration of isosorbide mononitrate, it can not only promote the development of endometrium tissue and improve the endometrial receptivity, but also effectively avoid the side effect of isosorbide mononitrate blood pressure drop. A new option is provided.

The invention discloses a targeted growth factor for promoting scar endometrium reconstruction of infertile women and an application of the targeted growth factor. The collagen-targeted basic fibroblast growth factor is a protein formed by fusing a basic fibroblast growth factor and a collagen binding domain. Experiments prove that after collagen-targeted basic fibroblast growth factor treatment,the menstrual blood volume, the endometrium thickness and the scar endometrium area of each infertility patient are all improved. Histological study shows that the blood vessel density is obviously increased. Three patients keep pregnancy 20 weeks after pregnancy. One patient gives birth to a healthy baby. The collagen-targeted basic fibroblast growth factor is injected into the endometrium in a multi-point mode, so that the angiogenesis capacity and proliferation capacity of the endometrium are improved, and the persistent pregnancy rate is increased.

The invention relates to the technical field of medicine preparation, and provides application of a formononetin derivative in preparation of a medicine for treating or preventing perimenopausal syndrome. The formononetin derivative can regulate the in-vivo estrogen balance of an estrogen imbalance individual, relieve the perimenopausal syndrome, increase the endometrium thickness or uterus weight in a uterine atrophy individual, regulate the osteogenesis and osteoclast balance of an osteoclast abnormal individual in bone tissue, and then improve osteoporosis and other symptoms caused by the perimenopausal syndrome. Meanwhile, the formononetin derivative has the advantages of being good in stability, suitable for patent medicine, good in biological activity and low in toxicity. The formononetin derivative is applied to development of the medicine for resisting the perimenopausal syndrome or used for preparing a reagent for researching the pathological mechanism of the perimenopausal syndrome and evaluating the curative effect of the perimenopausal syndrome, and has wide application prospects.

The invention belongs to the field of traditional Chinese medicine, and particularly relates to a drug for treating menstrual irregularity with protracted withdrawal symptoms. The drug comprises, by mass, 9-12g of bupleurum, 9-12g of cassia twig, 4-6g of dried ginger, 10-12g of trichosanthes kirilowii maxim, 6-9g of scutellaria baicalensis, 10-12g of oyster, 12-15g of prepared rehmannia root, 10-12g of ligusticum wallichii, 12-15g of fried angelica, 12-15g of radix paeoniae alba and 5-6g of honey-fried licorice root. A drug formula has the effects of strengthening the middle warmer, nourishingyin without greasiness, warming without dryness, achieving harmony between yin and yang, can effectively improve the endometrial thickness and the gonadal hormone concentration of a methamphetamine dependent patient, and achieves a significant treatment effect on the menstrual irregularity with protracted withdrawal symptoms and amenorrhea.

The invention belongs to the technical field of medicines, and particularly relates to a traditional Chinese medicine for treating hypomenorrhea after artificial abortion operation. The traditional Chinese medicine is prepared from the following traditional Chinese medicinal materials in parts by weight: 5-13 parts of incarvillea younghustandii sprague, 4-8 parts of taibai-gense, 4-8 parts of cinnamomum wilsonii, 4-8 parts of deer-horn glue, 5-13 parts of asarum wulingense, 5-13 parts of smilax nipponica, 4-8 parts of tsinling larkspur root, 4-8 parts of scaposum var. vaginatum, 5-13 parts of flavescent supplejack herb, 4-8 parts of gordon euryale leaves and 4-8 parts of licorice root, and the medicinal materials are combined to achieve the effects of tonifying kidneys, promoting blood circulation, warming channel and expelling cold. The traditional Chinese medicine closely focuses on the pathogenesis of hypomenorrhea due to kidney deficiency and cold in blood after artificial abortion operation, and can be used for remarkably improving the menstruation condition and increasing the thickness of endometrium.